Jarrod P. Holmes
Expertise in
48
conditions

Dr. Jarrod P. Holmes

Hematology Oncology | Hematology
3555 Round Barn Circle, Suite A, 
Santa Rosa, CA 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
48
conditions
3555 Round Barn Circle, Suite A, 
Santa Rosa, CA 

Overview

Jarrod Holmes is a Hematologist Oncology specialist and a Hematologist practicing medicine in Santa Rosa, California.

Dr. Holmes is highly rated in 48 conditions, according to our data. His clinical expertise encompasses Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia (CLL), Breast Cancer, Non-Hodgkin Lymphoma, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 9 peer reviewed articles and participating in 10 clinical trials. Dr. Holmes is currently accepting new patients.

Specialties

Hematology Oncology
Hematology

Licenses

Internal Medicine in IN

Hospital Affiliations

Providence Santa Rosa Memorial Hospital
Providence St Joseph Hospital
Healdsburg Hospital
Sonoma Valley Hospital
Adventist Health Ukiah Valley

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 8 Less Insurance Carriers -

Locations

3555 Round Barn Circle, Suite A, Santa Rosa, CA 95403

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
Enrollment Status: Completed
Publish Date: March 27, 2026
Intervention Type: Drug, Biological
Study Drugs: SV-BR-1-GM, INCMGA00012, Low Dose Cyclophosphamide, Interferon Inoculation, Epacadosta
Study Phase: Phase 1/Phase 2
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-322)
Enrollment Status: Active_not_recruiting
Publish Date: January 29, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Venetoclax, Rituximab
Study Phase: Phase 3
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Biological, Other
Study Drugs: Galinpepimut-S, Pembrolizumab
Study Phase: Phase 1/Phase 2
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Randomized Crossover Ph3 to Evaluate Efficacy/Safety of Enobosarm Monotherapy vs Active Control for Treatment of AR+/ER+/HER2- MBC With AR Staining Previously Treated w/Nonsteroidal Aromatase Inhibitor, SERD & CDK 4/6 Inhibitor
Enrollment Status: Terminated
Publish Date: January 26, 2024
Intervention Type: Drug
Study Drugs: Enobosarm, Exemestane
Study Phase: Phase 3
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Biological, Drug
Study Drugs: NeuVax vaccine, Trastuzumab, GM-CSF
Study Phase: Phase 2
A Phase 2 Exploratory Study of Intravenous QUZYTTIR™ (Cetirizine Hydrochloride Injection) Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions
A Phase 2 Exploratory Study of Intravenous QUZYTTIR™ (Cetirizine Hydrochloride Injection) Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Drug
Study Phase: Phase 2
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
P2 Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- MBC in Patients Who Have Shown Previous Disease Progression on a Nonsteroidal Aromatase Inhibitor, Fulvestrant and CDK 4/6 Inhibitor
Enrollment Status: Withdrawn
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: Sabizabulin, Exemestane, Everolimus, Selective estrogen receptor modulator
Study Phase: Phase 2
A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients
A Phase I/IIa Study of SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer Patients
Enrollment Status: Completed
Publish Date: January 29, 2021
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Combination Immunotherapy With Herceptin and the HER2 Vaccine E75 in Low and Intermediate HER2-expressing Breast Cancer Patients to Prevent Recurrence
Enrollment Status: Completed
Publish Date: December 02, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

9 Total Publications

Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer.
Results of a phase I/IIa trial of SV-BR-1-GM inoculation with low-dose cyclophosphamide and interferon alpha (Bria-IMT) in metastatic breast cancer.
Journal: Human vaccines & immunotherapeutics
Published: August 21, 2024
Similar Doctors
Expertise in
47
conditions
Dr. Leroy W. Keiser
Hematology Oncology | Hematology
Expertise in
47
conditions
Dr. Leroy W. Keiser
Hematology Oncology | Hematology
Referral may be required
Before you request
3555 Round Barn Circle, Suite A, 
Santa Rosa, CA 
 (0.1 miles away)
707-528-1050
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Leroy Keiser is a Hematologist Oncology specialist and a Hematologist practicing medicine in Santa Rosa, California. Dr. Keiser is highly rated in 47 conditions, according to our data. His clinical expertise encompasses Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Polycythemia Vera, and Richter Syndrome. Dr. Keiser is currently accepting new patients.

Expertise in
70
conditions
Dr. Mark Turrill
Hematology Oncology | Hematology
Expertise in
70
conditions
Dr. Mark Turrill
Hematology Oncology | Hematology
Referral may be required
Before you request
5150 Hill Road East, Suite F, 
Lakeport, CA 
 (41.0 miles away)
707-262-3060
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Turrill is a Hematologist Oncology specialist and a Hematologist practicing medicine in Lakeport, California. Dr. Turrill is highly rated in 70 conditions, according to our data. His clinical expertise encompasses Penile Cancer, Lynch Syndrome, Paget Disease of the Breast, and Richter Syndrome. Dr. Turrill is currently accepting new patients.

Expertise in
32
conditions
Dr. Wei Z. Ai
Hematology Oncology
Expertise in
32
conditions
Dr. Wei Z. Ai
Hematology Oncology
Referral may be required

Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program

400 Parnassus Ave., Fourth Floor, 
San Francisco, CA 
 (51.4 miles away)
415-353-2051
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Wei Ai is a blood cancer specialist who cares for adults with conditions such as Hodgkin's lymphoma and non-Hodgkin's lymphoma, including cutaneous lymphomas, which primarily involve the skin. She also sees patients needing blood and bone marrow transplantation. In her research, Ai focuses on novel approaches to lymphoma treatment, especially targeted agents for T-cell lymphomas. Her studies often lead to clinical trials of new therapies that target cancer at the molecular level. Ai earned a doctoral degree in microbiology and immunology as well as her medical degree from Stanford University School of Medicine. She completed a residency in internal medicine at UCSF, followed by fellowship training in medical oncology at Stanford. Dr. Ai is highly rated in 32 conditions, according to our data. Her clinical expertise encompasses Non-Hodgkin Lymphoma, Mycosis Fungoides, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ai is board certified in American Board Of Internal Med/Medical Oncology, Medical Oncology. Dr. Ai is currently accepting new patients.

Frequently Asked Questions about Dr. Jarrod P. Holmes

How do I make an appointment with Dr. Jarrod P. Holmes?

You can book an appointment with Dr. Jarrod P. Holmes by calling their office at 707-528-1050. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jarrod P. Holmes a top-rated expert for Waldenstrom Macroglobulinemia?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jarrod P. Holmes is classified as an Distinguished expert for Waldenstrom Macroglobulinemia, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jarrod P. Holmes specialize in?

While Dr. Jarrod P. Holmes is a Hematology Oncology, they have specific expertise in Waldenstrom Macroglobulinemia, Chronic Lymphocytic Leukemia (CLL), and Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Jarrod P. Holmes participate in research or clinical trials?

Yes. Dr. Jarrod P. Holmes has published 9 articles and abstracts on conditions like Waldenstrom Macroglobulinemia. You can view a list of Dr. Jarrod P. Holmes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jarrod P. Holmes accept my insurance?

Dr. Jarrod P. Holmes accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 707-528-1050 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Holmes's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 39 Advanced Conditions
    View All 131 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile